Image source: © 2025 Krish Capital Pty. Ltd.

Highlights

  • ATX’s FY25 interest income surged by 90.10% YoY, while total loss reached AUD 6.57 million.
  • ATX gained U.S. ethics approval to begin Phase 2 narmafotinib trial with FOLFIRINOX.
  • ATX is progressing its Phase II ACCENT trial of narmafotinib for pancreatic cancer treatment.
  • ATX share price increased by nearly 442% in a month and 471% in three months.

Amplia Therapeutics Limited (ASX:ATX) is an ASX-listed pharmaceutical company that develops FAK inhibitors to treat fibrotic cancers like pancreatic and ovarian cancer, as well as chronic diseases including idiopathic pulmonary fibrosis (IPF).

ATX stock price has increased by approximately 442.37 % over the past month and 263.63 % over the last six months. Notably, in a year, the stock price has shot up by 426.61%. The stock has a 52-week high and 52-week low of AUD 0.049 and AUD 0.425, respectively.

ATX shares closed at AUD 0.32 per share on 10 July 2025.

Recent Financial Performance

In the financial year 2025 (FY25), the company’s interest income surged by 90.10% YoY to AUD 0.28 million. The total loss for the year reached AUD 6.57 million, compared to AUD 4.50 million in FY24, primarily due to increased research and development expenses, primarily for the narmafotinib Phase II trial. The losses alos reflect investment in drug development. However, cash and cash equivalents surged by 220.89% YoY to AUD 10.86 million, up from AUD 3.39 million in FY24.

Business Update

ATX announced that its Phase 1b/2a ACCENT trial for advanced pancreatic cancer reported an additional confirmed partial response, bringing the total to 16.

On 24 June 2025, the company announced that it had received US ethics approval to begin a Phase 2 trial of narmafotinib with FOLFIRINOX, aiming to optimise dosing and outcomes.

Company Outlook

ATX is focused on advancing the Phase II ACCENT trial of narmafotinib to generate additional clinical data and expand patient enrollment for pancreatic cancer treatment. It also plans to launch a Phase 2 trial in the US combining narmafotinib with FOLFIRINOX, aiming to accelerate progress through regulatory approvals and site activations.

The company intends to optimise dosing strategies for narmafotinib to enhance safety and efficacy, supporting future regulatory submissions and commercialisation.

Top 10 Shareholders of ATX

The top 10 shareholders of ATX collectively hold approximately 34.81% of the company’s shares, with Platinum Asset Management and Acorn Capital Ltd. accounting for the largest portions at around 10.37% and 8.90%, respectively.

Support and Resistance Summary

Note 1: Past performance is not a reliable indicator of future performance.

Note 2: The reference data for all price data, currency, technical indicators, support, and resistance levels is 10 July 2025. The reference data in this report has been partly sourced from EODHD/Others.

 

Technical Indicators Defined

Support: A level at which the stock prices tend to find support if they are falling, and a downtrend may take a pause backed by demand or buying interest. Support 1 refers to the nearby support level for the stock and if the price breaches the level, then Support 2 may act as the crucial support level for the stock.

Resistance: A level at which the stock prices tend to find resistance when they are rising, and an uptrend may take a pause due to profit booking or selling interest. Resistance 1 refers to the nearby resistance level for the stock and if the price surpasses the level, then Resistance 2 may act as the crucial resistance level for the stock.